UroGen Pharma Ltd.

DB:UR8 Stock Report

Market Cap: €2.0b

UroGen Pharma Management

Management criteria checks 2/4

UroGen Pharma's CEO is Liz Barrett, appointed in Jan 2019, has a tenure of 7.58 years. total yearly compensation is $4.31M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth €13.27M. The average tenure of the management team and the board of directors is 6.2 years and 7.6 years respectively.

Key information

Liz Barrett

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage19.85%
CEO tenure7.6yrs
CEO ownership0.7%
Management average tenure6.2yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Liz Barrett's remuneration changed compared to UroGen Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$98m

Mar 31 2026n/an/a

-US$133m

Dec 31 2025US$4mUS$856k

-US$153m

Sep 30 2025n/an/a

-US$165m

Jun 30 2025n/an/a

-US$155m

Mar 31 2025n/an/a

-US$138m

Dec 31 2024US$4mUS$826k

-US$127m

Sep 30 2024n/an/a

-US$115m

Jun 30 2024n/an/a

-US$114m

Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$5mUS$794k

-US$102m

Sep 30 2023n/an/a

-US$105m

Jun 30 2023n/an/a

-US$109m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$2mUS$764k

-US$110m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$114m

Mar 31 2022n/an/a

-US$113m

Dec 31 2021US$4mUS$739k

-US$111m

Sep 30 2021n/an/a

-US$113m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$117m

Dec 31 2020US$2mUS$637k

-US$128m

Sep 30 2020n/an/a

-US$137m

Jun 30 2020n/an/a

-US$130m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$26mUS$695k

-US$105m

Compensation vs Market: Liz's total compensation ($USD4.31M) is above average for companies of similar size in the German market ($USD1.87M).

Compensation vs Earnings: Liz's compensation has increased whilst the company is unprofitable.

CEO

Liz Barrett (64 yo)

7.6yrs
Tenure
US$4,310,624
Compensation

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...

Leadership Team

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President7.6yrsUS$4.31m0.67%
€ 13.3m
Jason Smith
General Counsel6yrsUS$1.20m0.10%
€ 2.1m
Mark Schoenberg
Chief Medical Officer8.7yrsUS$1.17m0.25%
€ 4.9m
Christopher Degnan
Chief Financial Officer1.8yrsUS$1.43m0.0047%
€ 92.5k
Vincent Perrone
Senior Director of Investor Relationsno datano datano data
Alison Hardgrove
Senior Vice President of Human Resourcesless than a yearno datano data
Marina Konorty
Executive Vice President of Research & Development and Technical Operations6.4yrsno datano data
James Ottinger
Executive Vice President of Regulatory Affairs & Quality6.4yrsno datano data
Michael Louie
Chief Development Officer3yrsno datano data
Timothy Simon
Senior Vice President of Business Development & Portfolio Strategyno datano datano data
Ron Bentsur
Advisorno dataUS$699.77kno data
6.2yrs
Average Tenure
60yo
Average Age

Experienced Management: UR8's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President7.6yrsUS$4.31m0.67%
€ 13.3m
Cynthia Butitta
Independent Director8.8yrsUS$389.74k0.0041%
€ 81.2k
Stuart Holden
Independent Director10.7yrsUS$382.24k0.0041%
€ 81.2k
Arie Belldegrun
Independent Chairman13.7yrsUS$537.49k0.84%
€ 16.6m
Daniel Wildman
Independent Director3.8yrsUS$396.27k0.0041%
€ 81.2k
Jack Baniel
Member of Scientific Advisory Boardno datano datano data
Herbert Lepor
Chairman of Scientific Advisory Boardno datano datano data
Fred Witjes
Member of Scientific Advisory Boardno datano datano data
James Robinson
Independent Director3.1yrsUS$383.22k0.012%
€ 243.6k
Leana Wen
Independent Director4yrsUS$392.24k0.0041%
€ 81.2k
7.6yrs
Average Tenure
69yo
Average Age

Experienced Board: UR8's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/09 09:33
End of Day Share Price 2026/08/07 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

UroGen Pharma Ltd. is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Jason KolbertD. Boral Capital LLC.
Paul ChoiGoldman Sachs